Healthcare provider profile · identity verified

William Matthew James, MD

Internal Medicine · SAND SPRINGS, OK · NPI 1275591547

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Amlodipine Besylate	Amlodipine Besylate	859	249
Lisinopril	Lisinopril	430	118
Carvedilol	Carvedilol	383	114
Atorvastatin Calcium	Atorvastatin Calcium	382	113
Levothyroxine Sodium	Levothyroxine Sodium	360	87
Valsartan	Valsartan	299	88
Rosuvastatin Calcium	Rosuvastatin Calcium	292	95
Omeprazole	Omeprazole	282	88
Losartan Potassium	Losartan Potassium	281	80
Metoprolol Succinate	Metoprolol Succinate	269	76
Ozempic	Semaglutide	245	42
Gabapentin	Gabapentin	236	66
Furosemide	Furosemide	217	74
Duloxetine Hcl	Duloxetine Hcl	198	51
Pantoprazole Sodium	Pantoprazole Sodium	174	46
Escitalopram Oxalate	Escitalopram Oxalate	172	50
Metformin Hcl Er	Metformin Hcl	169	51
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	164	45
Hydralazine Hcl	Hydralazine Hcl	159	43
Eliquis	Apixaban	158	42
Albuterol Sulfate Hfa	Albuterol Sulfate	145	52
Potassium Chloride	Potassium Chloride	141	41
Tamsulosin Hcl	Tamsulosin Hcl	141	41
Metformin Hcl	Metformin Hcl	132	40
Hydrochlorothiazide	Hydrochlorothiazide	130	35
Glipizide	Glipizide	124	45
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	122	28
Fluticasone Propionate	Fluticasone Propionate	121	36
Trazodone Hcl	Trazodone Hcl	115	34
Methylprednisolone	Methylprednisolone	111	88
Xarelto	Rivaroxaban	111	23
Metoprolol Tartrate	Metoprolol Tartrate	109	33
Montelukast Sodium	Montelukast Sodium	109	30
Ibandronate Sodium	Ibandronate Sodium	107	38
Pravastatin Sodium	Pravastatin Sodium	101	33
Clopidogrel	Clopidogrel Bisulfate	80	26
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	78	23
Warfarin Sodium	Warfarin Sodium	77	18
Allopurinol	Allopurinol	69	20
Cephalexin	Cephalexin	68	55
Trulicity	Dulaglutide	63	14
Meloxicam	Meloxicam	57	13
Mounjaro	Tirzepatide	57	14
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	54	16
Citalopram Hbr	Citalopram Hydrobromide	50	14
Spironolactone	Spironolactone	50	14
Sertraline Hcl	Sertraline Hcl	47	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	46	13
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	43	13
Breo Ellipta	Fluticasone/Vilanterol	42	suppressed
Jardiance	Empagliflozin	42	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	38	14
Atenolol	Atenolol	37	11
Glipizide Er	Glipizide	36	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	35	suppressed
Tramadol Hcl	Tramadol Hcl	35	suppressed
Baclofen	Baclofen	34	13
Buspirone Hcl	Buspirone Hcl	34	suppressed
Alendronate Sodium	Alendronate Sodium	32	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	32	suppressed
Bupropion Xl	Bupropion Hcl	31	11
Digoxin	Digoxin	29	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	28	suppressed
Finasteride	Finasteride	28	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	27	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	27	suppressed
Synthroid	Levothyroxine Sodium	27	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	24	23
Estradiol	Estradiol	24	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	24	suppressed
Levofloxacin	Levofloxacin	24	21
Cefdinir	Cefdinir	23	20
Tresiba Flextouch U-100	Insulin Degludec	23	suppressed
Azithromycin	Azithromycin	22	21
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	22	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	22	suppressed
Benazepril Hcl	Benazepril Hcl	21	suppressed
Diclofenac Sodium	Diclofenac Sodium	21	suppressed
Lovastatin	Lovastatin	21	suppressed
Tresiba Flextouch U-200	Insulin Degludec	21	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	20	suppressed
Nebivolol Hcl	Nebivolol Hcl	19	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	19	14
Propranolol Hcl Er	Propranolol Hcl	19	suppressed
Ropinirole Hcl	Ropinirole Hcl	19	suppressed
Prednisone	Prednisone	18	14
Metoclopramide Hcl	Metoclopramide Hcl	17	suppressed
Novolog Flexpen	Insulin Aspart	17	suppressed
Arnuity Ellipta	Fluticasone Furoate	16	suppressed
Jantoven	Warfarin Sodium	16	suppressed
Nystatin	Nystatin	16	13
Ipratropium Bromide	Ipratropium Bromide	15	suppressed
Clindamycin Hcl	Clindamycin Hcl	14	13
Doxazosin Mesylate	Doxazosin Mesylate	14	suppressed
Ibuprofen	Ibuprofen	14	suppressed
Nitroglycerin	Nitroglycerin	14	suppressed
Ondansetron Odt	Ondansetron	14	12
Oxybutynin Chloride Er	Oxybutynin Chloride	14	suppressed
Valacyclovir	Valacyclovir Hcl	14	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	13	suppressed
Clonidine Hcl	Clonidine Hcl	13	suppressed
Fluconazole	Fluconazole	13	suppressed
Pregabalin	Pregabalin	13	suppressed
Torsemide	Torsemide	13	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	12	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	12	suppressed
Humalog Kwikpen U-100	Insulin Lispro	12	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	12	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	12	suppressed
Terazosin Hcl	Terazosin Hcl	12	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	12	12
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	12	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	11	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	11	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	11	suppressed
Levetiracetam	Levetiracetam	11	suppressed
Paroxetine Hcl	Paroxetine Hcl	11	suppressed
Soliqua 100-33	Insulin Glargine/Lixisenatide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error